Pipeline
Clinical Validation
Key: Currently underway / Planned / upcoming
GLP-1 Enhanced Delivery Program
Preclinical proof of biology — Fall 2026
Phase 1 — 2027–2028
N2B NAC Program
Phase 1A (Australia) — Complete by Q3 2026
Phase 1B (UCSF) — Starts Q2 2026 → Complete Q4 2026
★ NIH STTR grant funded Phase 1B — clinical-stage support; strong federal validation
Phase 2B (Cure Parkinson’s · Univ. of Bergen, Norway) — Expected Q2 2027
Our Pipeline
